

**Statements on funding and competing interests**

**Funding** The author has received honoraria and conference sponsorship from GlaxoSmithKline and Sanofi-Pasteur.

**Competing interests** The author is an investigator in the Cervarix trials. She is also Editor-in-Chief of the *Journal of Family Planning and Reproductive Health Care*.

**References**

- Salisbury D. Introduction of HPV vaccination into the national immunisation programme: vaccination of 17- to 18-year-old young women in 2008/09. DH letter GW 10266, 22 July 2008. [http://www.immunisation.nhs.uk/publications/HPV\\_DSletter220708.pdf](http://www.immunisation.nhs.uk/publications/HPV_DSletter220708.pdf) [Accessed 22 August 2008].
- Hansard, Columns 531W, 532W, 16 July 2008. <http://www.publications.parliament.uk/pa/cm200708/cmhansrd/cm080716/text/80716w0028.htm> [Accessed 22 August 2008].
- Hawkes N. GlaxoSmithKline wins NHS contract to supply cervical cancer vaccine. *The Times*, 18 June 2008. [http://www.timesonline.co.uk/tol/life\\_and\\_style/health/article4166423.ece](http://www.timesonline.co.uk/tol/life_and_style/health/article4166423.ece) [Accessed 22 August 2008].
- Boseley S. Decision on cervical cancer vaccine is false economy, say health groups. *The Guardian*, 18 July 2008. <http://www.guardian.co.uk/science/2008/jul/18/cancer.medicalresearch> [Accessed 22 August 2008].
- Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. *BMJ* 2008; **337**: a769.
- Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, *et al.* Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. *BMJ* 2008; **336**: 1056–1058.
- Kane MA. Human papillomaviruses (HPV) vaccines: implementation and communication issues *J Fam Plann Reprod Health Care* 2008; **34**: 3–4.
- Stanley M. HPV vaccines: where are we now? *J Fam Plann Reprod Health Care* 2007; **33**: 227–229.
- Einstein MH. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. *Cancer Immunol Immunother* 2008; **57**: 443–451.
- Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. *N Engl J Med* 2008; **359**: 821–832.
- Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D, *et al.* Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: long-term follow-up through 6.4 years in women vaccinated with CERVARIX (GSK's HPV 16/18 AS04 candidate vaccine). Oral presentation at the Society of Gynecologic Oncologists Annual Meeting on Women's Cancer, Tampa, FL, USA, 10 March 2008 [Abstract in *Gynecol Oncol* 2008; **109**: 158].
- Brown D. HPV Type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma *in situ* (AIS) caused by oncogenic HPV types in addition to 16/18. Oral presentation at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, USA, 17–20 September 2007 [Abstract G-1720b, 19 September 2007].
- Gardasil Product Monograph. 8 May 2008. [http://www.merckfrosst.ca/assets/en/pdf/products/GARDASIL\\_1127-a\\_3\\_08-E.pdf](http://www.merckfrosst.ca/assets/en/pdf/products/GARDASIL_1127-a_3_08-E.pdf) [Accessed 22 August 2008].
- Luna J, Saah A, Hood S, Barr E. Safety, efficacy and immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24–45. Oral presentation at the 24th International Papillomavirus Congress, 3–9 November 2007, Beijing, China [Abstract PA1-04].
- Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, *et al.* Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. *Int J Cancer* 2007; **121**: 621–632.

## FACULTY OF SEXUAL & REPRODUCTIVE HEALTHCARE MEMBERSHIP EXAMINATION

The Membership Examination (MFSRH) consists of:

### ☐ Part 1 Multiple Choice Question paper (MCQ)

This 1½-hour paper consists of 60 clinical science and applied science questions.

The London-based examination will be on **Wednesday 22 April 2009** (the Faculty must receive applications by **1 January 2009**) and on **Friday 16 October 2009** (the Faculty must receive applications by **1 July 2009**). The application form and information on the Part 1 can be obtained from the Faculty of Sexual and Reproductive Healthcare (FSRH) website ([www.fsrh.org](http://www.fsrh.org)).

### ☐ Evidence Based Commentary (EBC)

The Evidence Based Commentary replaces the case reports/dissertation component of the Membership examination and candidates can now view the first annually released topic on the Faculty website. Candidates have an absolute deadline of 31 August the following year to submit the Commentary on this topic. The Commentary must be a minimum of 1000 words and a maximum of 2000 words, excluding references, tables and appendices, and the format must follow the guidance notes. Candidates can find detailed information in the Candidate Guidance Notes for Evidence Based Commentary and the Membership Examination Regulations (September 2008) on the Faculty website.

### ☐ Part 2 Examination (CRQ, SAQ, OSCE)

This all-day examination consists of:

- Critical Reading Question examination paper (CRQ)
- Short Answer Question examination paper (SAQ)
- Objective Structured Clinical Examination (OSCE)

The Faculty must receive applications for the Part 2 to be held on **Thursday 4 June 2009** by **3 January 2009**. Information on the Part 2 examination, the Examination Regulations and the application form appear on the Faculty website.

The qualification is subject to re-certification every 5 years.

For the current MFSRH Examination Regulations (September 2008), information on all components of the MFSRH examination and application forms, please visit the FSRH website: [www.fsrh.org](http://www.fsrh.org) (see **Training & Exams** and **Membership Exam**) or e-mail Denise Pickford at [denise@fsrh.org](mailto:denise@fsrh.org). Examinations, Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG, UK. Tel: +44 (0) 20 7724 5629. Fax: +44 (0) 20 7723 5333.